In development: Guidance, quality standards and advice
Showing 91 to 96 of 96
| Title | Type | Expected publication date |
|---|---|---|
| Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Technology appraisal guidance | TBC |
| Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
| Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557] | Technology appraisal guidance | TBC |
| Venous thromboembolism in over 16s : aspirin following orthopaedic surgery (update) | NICE guideline | TBC |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] | Technology appraisal guidance | |
| Vosoritide for treating achondroplasia in people 4 months and over [ID6488] | Technology appraisal guidance | TBC |